NCT05254314View on ClinicalTrials.gov

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

April 30, 2026

Conditions
Asthma
Interventions
DRUG

Semaglutide Pen Injector 2.4mg weekly

Once weekly subcutaneous injection

OTHER

Placebo

Once weekly subcutaneous injection

Trial Locations (1)

37203

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Vanderbilt University Medical Center

OTHER